2022
DOI: 10.1016/j.jcv.2022.105318
|View full text |Cite
|
Sign up to set email alerts
|

Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
5
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 14 publications
0
5
0
1
Order By: Relevance
“…Using primers specific to the hexon region, this study confirmed the presence of HAdV type 8 from Group D in an ocular swab specimen. (Figure .1) Prior research conducted in India found that 78.6% of people in Pune and 100% in Pondicherry were affected by type 8 [16,17].…”
Section: Figure 1: Neighbor-joining Bootstrap Consensus Phylogenetic ...mentioning
confidence: 96%
“…Using primers specific to the hexon region, this study confirmed the presence of HAdV type 8 from Group D in an ocular swab specimen. (Figure .1) Prior research conducted in India found that 78.6% of people in Pune and 100% in Pondicherry were affected by type 8 [16,17].…”
Section: Figure 1: Neighbor-joining Bootstrap Consensus Phylogenetic ...mentioning
confidence: 96%
“…Another study conducted at Aravind Eye Center in Madurai, India showed the association between conjunctivitis and covid in almost 11% of the patients. Along with conjunctival scarring covid can also cause optic neuritis, uveitis, and keratitis [43][44][45][46] .…”
Section: Conjunctivitis Association With Covidmentioning
confidence: 99%
“…Em nossos resultados, as características ou sintomas mais comuns foram; epífora que oscilou entre 15% e 86% (Lalitha et al, 2022;Prajna et al, 2022;Ranzenigo et al, 2021), seguida de corpo estranho que atingiu entre 11,8% e 57,1% (Almazroa et al, 2022;Jin et al, 2021;Panoutsopoulos, 2020), secreção de 26,8% a 38,5% (Aggarwal et al, 2020;Jin et al, 2021;Prajna et al, 2022), coceira de 46% para 71% (Lalitha et al, 2022;Prajna et al, 2022), dor ocular que foi de 11,2% para 31,2% % (Aggarwal et al, 2020;Lalitha et al, 2022;Ranzenigo et al, 2021), hiperemia de 11,2% para 26,8% (Aggarwal et al, 2020;Binotti & Hamrah, 2022;Layikh et al, 2021;Mocanu et al, 2022;Ranzenigo et al, 2021), olho seco de 9,8% a 33,3% (Almazroa et al, 2022;Inomata et al, 2020), olho pegajoso com 10% (Ranzenigo et al, 2021), congestão conjuntival entre 5,0% a 28,8% % (Binotti & Hamrah, 2022;Chen et al, 2020;Jin et al, 2021;Layikh et al, 2021), visão turva que chegou a 12,7%…”
Section: Métodounclassified